Drug Profile


Alternative Names: BHV-4157

Latest Information Update: 05 Jun 2017

Price : $50

At a glance

  • Originator Yale University
  • Developer Biohaven Pharmaceutical Holding Company
  • Class Benzothiazoles; Small molecules
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinocerebellar degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Spinocerebellar degeneration

Most Recent Events

  • 30 May 2017 Biohaven Pharmaceutical completes enrolment in its phase II/III trial for Spinocerebellar ataxia in USA
  • 15 May 2017 Trigriluzole receives Fast Track designation for Spinocerebellar degeneration [PO] in USA
  • 22 Dec 2016 Phase-II/III clinical trials in Spinocerebellar degeneration (spinocerebellar ataxia) in USA (PO) (NCT02960893)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top